Bio Preventive Medicine Corp.
Bio Preventive Medicine Corp., a clinical-staged biotech company, focusing on early detection and prevention of diseases. The company offers solutions in prevention, screening, and monitoring chronic diseases and cancers management. It also provides DNlite test, a series of patented and clinically validated non-invasive urine test for monitoring the progression of diabetic nephropathy, including … Read more
Bio Preventive Medicine Corp. (6810) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of June 2025: -0.138x
Based on the latest financial reports, Bio Preventive Medicine Corp. (6810) has a cash flow conversion efficiency ratio of -0.138x as of June 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (NT$-49.42 Million) by net assets (NT$358.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Bio Preventive Medicine Corp. - Cash Flow Conversion Efficiency Trend (2020–2024)
This chart illustrates how Bio Preventive Medicine Corp.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Bio Preventive Medicine Corp. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bio Preventive Medicine Corp. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
ORION ENRGY SYS
BE:5A4
|
-0.155x |
|
CHINA COMM SRVCS-H
MU:CMW
|
N/A |
|
Perk International Inc
PINK:PRKI
|
0.349x |
|
KASATI
VN:KST
|
N/A |
|
ICDS Limited
NSE:ICDSLTD
|
0.021x |
|
National Development Bank PLC
CM:NDBN0000
|
N/A |
|
Pakistan Cables Ltd
KAR:PCAL
|
N/A |
|
Bera Holding AS
IS:BERA
|
-0.006x |
Annual Cash Flow Conversion Efficiency for Bio Preventive Medicine Corp. (2020–2024)
The table below shows the annual cash flow conversion efficiency of Bio Preventive Medicine Corp. from 2020 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | NT$407.09 Million | NT$-66.95 Million | -0.164x | +63.41% |
| 2023-12-31 | NT$139.93 Million | NT$-62.90 Million | -0.450x | -15.65% |
| 2022-12-31 | NT$140.54 Million | NT$-54.63 Million | -0.389x | -19.61% |
| 2021-12-31 | NT$137.94 Million | NT$-44.83 Million | -0.325x | -41.85% |
| 2020-12-31 | NT$201.77 Million | NT$-46.23 Million | -0.229x | -- |